Get started
Work

28RO Bulumtatug fuvedotin (BFv, 9MW2821), a nectin-4 antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: Updated results from a phase I/II study

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Bulumtatug Fuvedotin (BFv, 9MW2821) is a monoclonal antibody-drug conjugate that delivers MMAE to cells expressing Nectin-4. The preliminary results of our study were presented at SGO 2024, demonstrating promising antitumor activity (unconfirmed ORR: 40.54% in 37 patients) and manageable tolerability in patients with cervical cancer. Herein, we predominantly update the efficacy data.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2026.108054
Authors: H. Yang, J. Zhang, R. Liu, S. Gao, H. Lou, G. Li, H. Bu, R. Li, S. Cheng, J. Chen, S. Wang, S. Shen, X. Li, C. Hu, M. Zhang, S. Wang, P. Wang, N. Chu
Institutions: Fudan University Shanghai Cancer Center, Zhejiang Cancer Hospital, University of Chinese Academy of Sciences, Wuhan Union Hospital, Huazhong University of Science and Technology, Shandong University, Qilu Hospital of Shandong University, Chongqing University, Chongqing Cancer Hospital, Zhengzhou University, Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Second People’s Hospital of Yibin, First Affiliated Hospital of Zhengzhou University, University of Science and Technology of China, Anhui Provincial Hospital, Anhui Medical University
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7167055765
FWCI:
Cites:
Cited by:
Related to: